Endometrial Cancer News and Research

RSS

Sitting around could be waiting for cancer to strike say researchers

A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.

6 Nov 2011

iCAD, Hitachi enter distribution agreement for MRI breast cancer diagnosis and guided biopsy solution

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that it has entered into a distribution agreement with Hitachi Medical Systems.

31 Oct 2011

Weight gain during adulthood may increase risk of endometrial cancer in women

Postmenopausal women who gained weight during adulthood had an increased risk for endometrial cancer compared with women who maintained a stable weight, according to data from the American Cancer Society's Cancer Prevention Study II Nutrition Cohort.

24 Oct 2011

Latest findings on cancer to be presented at 10th AACR international conference

What: The 10th AACR International Conference on Frontiers in Cancer Prevention Research will bring together scientists to share the latest findings in genetics, chemoprevention and lifestyle choices that may prevent cancer.

4 Oct 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

IUDs may protect from cervical cancer

According to the results of an international study, coil contraceptive devices might protect women against developing cervical cancer even though they don't stop the infection that commonly leads to the disease.

14 Sep 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Aeterna Zentaris Inc. today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology, to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

19 Jul 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density due to anorexia nervosa in teenage girls with the disease when given as a patch or as a low oral dose that is physiological.

6 Jun 2011

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Ipsen today announced its decision to assess the alternative development of Irosustat (BN 83495) in combination with other hormonal therapies. This decision is based on the futility analysis from the proof-of-concept trial phase II clinical study carried out in Europe in monotherapy in endometrial cancer, and on the phase I/II clinical study results obtained in metastatic prostate and breast cancers.

6 Jun 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

6 Jun 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

TGen licenses ONCO-101 cancer drug to Syracuse

The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

5 May 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

First ever genome scan for womb cancer reveals genetic region that reduces risk of the disease

Scientists have carried out the first ever genome scan for womb cancer and discovered a genetic region that reduces risk of the disease, according to a study published in Nature Genetics.

18 Apr 2011

Varian Medical Systems launches new brachytherapy applicator

Varian Medical Systems is introducing a new brachytherapy applicator for treating endometrial cancer patients after a hysterectomy. The Capri applicator, aimed at increasing patient comfort and allowing clinicians to better sculpt the radiotherapy dose, is being exhibited this week at the annual American Brachytherapy Society meeting in San Diego.

15 Apr 2011

Endometrial Cancer News and Research

Sitting around could be waiting for cancer to strike say researchers

iCAD, Hitachi enter distribution agreement for MRI breast cancer diagnosis and guided biopsy solution

Weight gain during adulthood may increase risk of endometrial cancer in women

Latest findings on cancer to be presented at 10th AACR international conference

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

IUDs may protect from cervical cancer

Alnylam second quarter revenue decreases to $20.6 million

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Cancer risk assessment in Lynch syndrome

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Ipsen decides to assess development of Irosustat in combination with hormonal therapies

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

TGen licenses ONCO-101 cancer drug to Syracuse

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

First ever genome scan for womb cancer reveals genetic region that reduces risk of the disease

Varian Medical Systems launches new brachytherapy applicator

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News